Muromachi Chemicals Inc. (TSE:4885) has raised its full-year earnings forecast for the fiscal period ending May 2026, citing strong order intake across its chemical and pharmaceutical businesses.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 7.50bn | JPY 7.70bn | +2.7% |
| Operating Profit | JPY 550M | JPY 700M | +27.3% |
| Ordinary Income | JPY 510M | JPY 660M | +29.4% |
| Net Profit | JPY 350M | JPY 470M | +34.3% |
| EPS | ¥87.14 | ¥117.02 | — |
This upward revision reflects stronger-than-expected performance in its core chemical and pharmaceutical segments, driven by order intake that exceeded prior expectations. Additionally, the company noted that costs associated with its exit from the health food business are lower than initially anticipated, contributing to improved profitability.
The revision underscores Muromachi Chemicals’ confidence in its operational performance and strategic adjustments, signaling a commitment to balancing growth with shareholder returns. Investors should note that the company’s financial reporting includes Japan-specific metrics such as ordinary income (keijo rieki), which incorporates non-operating items like interest and dividend income, differing from international standards.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.